Alasdair P. MacGowan, Caroline Rynn, Mandy Wootton, Karen E. Bowker, H

Slides:

Advertisements

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Advertisements

Laboratory diagnosis and biosafety issues of biological warfare agents

Metallo-β-lactamase-producing Pseudomonas aeruginosa in the Netherlands: the nationwide emergence of a single sequence type A.K. Van der Bij, D. Van.

Development of resistance in Pseudomonas aeruginosa obtained from patients with cystic fibrosis at different times F.B. Spencker, L. Staber, T. Lietz,

Approach to diagnosis of infective endocarditis

The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram- positive bacteria M.J. Rybak Clinical Microbiology and Infection

Herpes zoster in non-hospitalized children

In vitro activity of several antimicrobial peptides against colistin-susceptible and colistin- resistant Acinetobacter baumannii X. Vila-Farres, C. Garcia.

Antimicrobial Activity of SCH 27899, Oligosaccharide Member of the Everninomycin Class with a Wide Gram-Positive Spectrum Ronald N. Jones, M.D., Mary.

In vitro activity of cefpirome and vancomycin in combination against gentamicin- susceptible and gentamicin-resistant Staphylococcus aureus A. Carricajo,

Use of antimicrobials and resistance in bacteria isolated from blood cultures in a Danish county from 1992 to 1995 Thomas Lund S⊘rensen, Niels Frimodt-M⊘ller,

Hydatid disease Clinical Microbiology and Infection

How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development R. Bax Clinical Microbiology.

How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach D. Guillemot Clinical Microbiology.

In vitro activity, postantibiotic effect and human monocyte activity of grepafloxacin against Legionella species Jacques Dubois, Claude St-Pierre Clinical.

Trends in antibiotic prescribing in general internal medicine wards: antibiotic use and indication for prescription B. Maraha, M. Bonten, H. Fiolet,

Holt Hanne M. , Søgaard Per , Gahrn-Hansen Bente

Effect of moxifloxacin on secretion of cytokines by human monocytes stimulated with lipopolysaccharide F.G. Araujo, T.L. Slifer, J.S. Remington Clinical.

Structure of grepafloxacin relative to activity and safety profile

Vector control: a cornerstone in the malaria elimination campaign

C-3′Quaternary Ammonium Cephems, a New Wave of Cephalosporins

Multicenter study of the in vitro activity of cefepime in comparison with five other broad- spectrum antibiotics against clinical isolates of Gram-positive.

Training for the infectious diseases speciality in Norway

The antibacterial effects of ciprofloxacin and trovafloxacin against Streptococcus pneumoniae in an in vitro dynamic model Matthew O'Brien, Thuy Quach,

Cephalosporins: a pharmacological update

Epidemiology of opportunistic infections in AIDS patients

Laboratory diagnosis and biosafety issues of biological warfare agents

CMI editorial report 2011 Clinical Microbiology and Infection

In vitro selective concentrations of cefepime and ceftazidime for AmpC β-lactamase hyperproducer Enterobacter cloacae variants Maria-Cristina Negri,

Comparative in vitro pharmacodynamics of BO-2727, meropenem and imipenem against Gram-positive and Gram-negative bacteria Inga Odenholt, Elisabeth Löwdin,

Sepsis and neutropenia induced by clozapine

A comparative study of the in vitro activity of meropenem and representatives of the major classes of broad-spectrum antibiotics J. Moira Greenhalgh,

Uncommon opportunistic fungi: new nosocomial threats

Elements of design: the knowledge on which we build

In vitro selection of antibiotic resistance in Pseudomonas aeruginosa

Levofloxacin in the treatment of ventilator-associated pneumonia

Effect of antioxidants on the immune response of Helicobacter pylori

Laboratory diagnosis of Clostridium difficile disease

Antimicrobial susceptibility of non-Bacteroides fragilis group anaerobic Gram-negative bacilli in Europe Anna King, Julie Downes, Carl-Erik Nord, Ian.

W.A. Craig Clinical Microbiology and Infection

Recent developments in staphylococcal scalded skin syndrome

S8 – S47 and O50 – O440 Clinical Microbiology and Infection

Interactions between cytomegalovirus and the p53 tumor suppressor gene in atherosclerotic vascular disease Inge O. Baas, G. Johan A. Offerhaus, Ralph.

Pathogenesis of catheter-related infections: lessons for new designs

Single- and multistep selection study of the antipneumococcal activity of BMS compared to ciprofloxacin, levofloxacin, trovafloxacin and moxifloxacin

Community-acquired pneumonia: epidemiologic and clinical consideration

Abstracts cont. Clinical Microbiology and Infection

Single-dose ciprofloxacin versus 3 days of norfloxacin in uncomplicated urinary tract infections in women F. Auquer, F. Cordón, E. Gorina, J.C. Caballero,

Lack of antimicrobial activity of sodium heparin for treating experimental catheter-related infection due to Staphylococcus aureus using the antibiotic-lock.

Antimicrobial drug development – the past, the present, and the future

Clinical infection services—the Leiden experience

Ethan Rubinstein, Itzhak Levy Clinical Microbiology and Infection

Outpatient and home parenteral antibiotic therapy (OHPAT) in the UK: a consensus statement by a working party Dilip Nathwani, Christopher Conlon Clinical.

European guidelines for diagnosis and management of patients with suspected herpes simplex encephalitis Miles Denton, Kevin G Kerr, Fraser Lewis Clinical.

Clinical Microbiology and Infection

Overview of cefixime use in community-acquired infections

The in vitro activity of moxifloxacin against Haemophilus influenzae and Moraxella catarrhalis explored using a pharmacodynamic model Alasdair P. MacGowan,

The atypical pneumonias: clinical diagnosis and importance

Facilitating learning and change in physicians: Implications for a system of continuing medical education in Europe Robert D. Fox Clinical Microbiology.

Abstracts Clinical Microbiology and Infection

New oral cephalosporins in pediatric community-acquired infections

Carratalà J. Clinical Microbiology and Infection

B.A. Cunha Clinical Microbiology and Infection

J.L. Balcázar Clinical Microbiology and Infection

G.C. Schito Clinical Microbiology and Infection

Gebhard Feierl, Christian Berghold, Theresia Fürpaβ, Egon Marth

Impact of antibiotic restrictions: the patient's perspective

Outpatient and home parenteral antibiotic therapy (OHPAT) in the UK: a consensus statement by a working party Dilip Nathwani, Christopher Conlon Clinical.

The future of diagnostic bacteriology

Vincent Calvez, Marc Grandadam Clinical Microbiology and Infection

Presentation transcript:

In vitro assessment of colistin's antipseudomonal antimicrobial interactions with other antibiotics Alasdair P. MacGowan, Caroline Rynn, Mandy Wootton, Karen E. Bowker, H. Alan Holt, David S. Reeves Clinical Microbiology and Infection Volume 5, Issue 1, Pages 32-36 (January 1999) DOI: 10.1111/j.1469-0691.1999.tb00095.x Copyright © 1999 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 1 Time kill kinetics of colistin (C) at concentration of 0.5 mg/L (0.5) and 5 mg/L (5) plus: (a) ceftazidime (CEF) at concentrations of 1 mg/L (1) and 75 mg/L (75); (b) aztreonam (AZT) at concentrations of 1 mg/L (1) and 30 mg/L (30); (c) meropenem (MER) at concentrations of 1 mg/L (1) and 25 mg/L (25); (d) piperacillin (PIP) at concentrations of 5 mg/L (5) and 100 mg/L (100); (e) gentamicin (GEN) at concentrations of 1 mg/L (1) and 10 mg/L (10); (f) ciprofloxacin (CIP) at concentrations of 0.25 mg/L (0.25) and 4 mg/L (4). GC is the growth control. Clinical Microbiology and Infection 1999 5, 32-36DOI: (10.1111/j.1469-0691.1999.tb00095.x) Copyright © 1999 European Society of Clinical Infectious Diseases Terms and Conditions